Cosentyx (secukinumab) is a biologic medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug works by blocking interleukin-17A, a protein that plays a role in inflammation. While Cosentyx has been shown to be effective in treating these conditions, there are potential risks associated with its use during pregnancy.

According to Drugs.com [2], Cosentyx has been assigned a pregnancy category B classification by the FDA, which means that animal studies have not shown any evidence of harm to the fetus, but there are no well-controlled studies in pregnant women. However, a study published in the Journal of Dermatological Treatment [3] found that Cosentyx may be associated with an increased risk of adverse pregnancy outcomes, including preterm birth, low birth weight, and fetal abnormalities.

The study analyzed data from 23 women who had received Cosentyx during pregnancy. Of these women, six had adverse pregnancy outcomes, including two cases of preterm birth, two cases of low birth weight, and two cases of fetal abnormalities. While this is a small sample size, the study suggests that there may be a potential risk associated with Cosentyx use during pregnancy.

The drug patent watch [1] also mentions that "there are no adequate and well-controlled studies in pregnant women," and "Cosentyx should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." The drug patent watch also states that Cosentyx is excreted into human milk, and women should be advised to either discontinue the drug or stop breastfeeding while taking it.

In conclusion, while Cosentyx has not been shown to cause harm to the fetus in animal studies, there is limited data available on its use during pregnancy in humans. The available data suggests that there may be an increased risk of adverse pregnancy outcomes associated with Cosentyx use. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of Cosentyx with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.drugs.com/pregnancy/secukinumab.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/